Hearing aids may lower dementia risk for some older adults, but the honest answer is "not for everyone, and not yet proven." The strongest trial to date found no overall slowing of cognitive decline, yet a clear benefit among people already at higher risk. That distinction matters more than the headlines. This page explains what the evidence actually shows, who stands to benefit, and where the limits are. It also covers a practical shift that makes hearing aids easier to obtain than they were a few years ago.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the strongest study actually found
- Why some people benefited and others did not
- How hearing loss fits the wider dementia picture
- The limits of the evidence
- What an older adult can practically do
- Frequently Asked Questions
What the strongest study actually found
The clearest evidence comes from ACHIEVE, the first randomized controlled trial testing whether treating hearing loss slows cognitive decline. A randomized controlled trial randomly assigns people to a treatment or a comparison group, which reduces bias. According to the ACHIEVE trial published in The Lancet, researchers enrolled 977 adults aged 70 to 84 with untreated mild-to-moderate hearing loss and followed them for three years. Half received hearing aids plus rehabilitation.
Half received a health-education program instead. Over three years, the two groups did not differ significantly in the primary measure of cognitive decline. In plain terms, the sweeping claim that "hearing aids lower dementia risk" for all older adults is not supported by this trial. That is the single most important thing to take away before reading any further.
Why some people benefited and others did not
The trial drew participants from two groups. One was a set of older adults already enrolled in a long-running heart-health study, who were older and at higher risk of decline. The other was a group of healthier volunteers recruited specifically for the trial. Among the higher-risk participants, hearing intervention slowed three-year cognitive decline by roughly 48 percent.
Among the healthier volunteers, it showed no effect. A later secondary analysis in Alzheimer's & Dementia found that in the top risk quartile, decline was about 58 percent slower with hearing treatment. The National Institute on Aging summarized the pattern plainly: the benefit was concentrated in those at higher risk, not the general population. So the same treatment helped one group meaningfully and did nothing measurable for the other.
How hearing loss fits the wider dementia picture
Zoom out from one trial and hearing loss still stands out. The 2024 Lancet Commission on dementia ranks hearing loss as the largest single modifiable risk factor in midlife, among 14 factors it identifies. According to the 2024 Lancet Commission summary, addressing all 14 factors together could in theory prevent about 45 percent of dementia cases. Read that number carefully.
It reflects population-level association, not proof that any one action prevents dementia in an individual. Association means the two things tend to occur together. It does not establish that hearing loss causes dementia, or that fixing hearing reverses that risk. Both the Commission's estimate and the ACHIEVE result point in a hopeful direction without closing the case.
The limits of the evidence
ACHIEVE measured the rate of cognitive decline over three years. It did not measure how many people developed dementia, and it was not long enough or designed to prove that hearing aids prevent dementia as a diagnosis. It also found no measurable benefit to brain volume on imaging.
That absence leaves the biological mechanism unsettled. We can see an effect on thinking scores in higher-risk people without yet knowing exactly why. None of this makes hearing treatment pointless. It simply means the honest framing is "promising for some, unproven for prevention," not "proven to stop dementia.".
- The overall trial result was neutral, not positive.
- The benefit appeared only in higher-risk older adults.
- The endpoint was cognitive-decline rate, not dementia diagnosis.
- No brain-volume benefit was detected.
What an older adult can practically do
Getting hearing checked is now easier than it was. In 2022 the FDA created a new over-the-counter category, so adults can buy certain devices without an exam or prescription. According to the FDA's final rule, effective October 17, 2022, over-the-counter hearing aids are available to adults 18 and older who perceive mild-to-moderate hearing loss.
That lowers the cost and hassle of a first step. Better hearing has real, immediate value regardless of the dementia question. The possible brain benefit for higher-risk people is a reason to act sooner, not a promise to bank on.
- If you notice trouble following conversations, ask a clinician for a hearing test.
- Treat clear hearing loss on its own merits — communication, safety, and quality of life.
- If you are older or already at higher risk of cognitive decline, discuss the ACHIEVE findings with your doctor.
- Do not expect a hearing aid to guarantee protection against dementia.
Frequently Asked Questions
Does treating hearing loss prevent dementia?
No study has proven that. ACHIEVE measured cognitive-decline rate, not dementia diagnoses, and found benefit only in higher-risk older adults.
Should I get hearing aids just to protect my brain?
Treat hearing loss for its own benefits first. If you are at higher risk of decline, the possible cognitive benefit is worth discussing with your doctor.
Do I need a prescription to try hearing aids?
Not always. Since October 2022, FDA-authorized over-the-counter hearing aids are available to adults with perceived mild-to-moderate loss without an exam.
